A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.